Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.
Share
Why It Matters
A big investment bank started watching Entera Bio and likes what it sees. They picked a target price, which shows they think the company might do well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.